BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33658300)

  • 1. Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy.
    Young C; Wood HM; Fuentes Balaguer A; Bottomley D; Gallop N; Wilkinson L; Benton SC; Brealey M; John C; Burtonwood C; Thompson KN; Yan Y; Barrett JH; Morris EJA; Huttenhower C; Quirke P
    Clin Cancer Res; 2021 Apr; 27(8):2246-2254. PubMed ID: 33658300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries.
    Young C; Wood HM; Seshadri RA; Van Nang P; Vaccaro C; Melendez LC; Bose M; Van Doi M; Piñero TA; Valladares CT; Arguero J; Balaguer AF; Thompson KN; Yan Y; Huttenhower C; Quirke P
    Genome Med; 2021 Feb; 13(1):27. PubMed ID: 33593386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening.
    Grobbee EJ; Lam SY; Fuhler GM; Blakaj B; Konstantinov SR; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC
    United European Gastroenterol J; 2020 Apr; 8(3):293-302. PubMed ID: 32213018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High test positivity and low positive predictive value for colorectal cancer of continued faecal occult blood test screening after negative colonoscopy.
    Brown JP; Wooldrage K; Wright S; Nickerson C; Cross AJ; Atkin WS
    J Med Screen; 2018 Jun; 25(2):70-75. PubMed ID: 28467146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants.
    Kværner AS; Birkeland E; Bucher-Johannessen C; Vinberg E; Nordby JI; Kangas H; Bemanian V; Ellonen P; Botteri E; Natvig E; Rognes T; Hovig E; Lyle R; Ambur OH; de Vos WM; Bultman S; Hjartåker A; Landberg R; Song M; Blix HS; Ursin G; Randel KR; de Lange T; Hoff G; Holme Ø; Berstad P; Rounge TB
    BMC Cancer; 2021 Aug; 21(1):930. PubMed ID: 34407780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study.
    Goedert JJ; Gong Y; Hua X; Zhong H; He Y; Peng P; Yu G; Wang W; Ravel J; Shi J; Zheng Y
    EBioMedicine; 2015 Jun; 2(6):597-603. PubMed ID: 26288821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.
    Geraghty J; Butler P; Seaman H; Snowball J; Sarkar S; Blanks R; Halloran S; Bodger K; Rees CJ
    Br J Cancer; 2014 Nov; 111(11):2156-62. PubMed ID: 25225905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing.
    Taylor M; Wood HM; Halloran SP; Quirke P
    J Clin Pathol; 2017 Jul; 70(7):600-606. PubMed ID: 28011577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
    Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
    Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of guaiac-based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Am J Gastroenterol; 2014 Mar; 109(3):427-35. PubMed ID: 24343548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
    Almansoori A; Alzaabi M; Alketbi L
    BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme.
    Kearns B; Whyte S; Chilcott J; Patnick J
    Br J Cancer; 2014 Oct; 111(9):1734-41. PubMed ID: 25180767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using fecal immunochemical tubes for the analysis of the gut microbiome has the potential to improve colorectal cancer screening.
    Krigul KL; Aasmets O; Lüll K; Org T; Org E
    Sci Rep; 2021 Oct; 11(1):19603. PubMed ID: 34599256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
    Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.